Today marks the successful launch of the OP-Zuid project STIM-00953, “Laprixa, the Intra-operative Predictor of Wound Healing Capacity”!

Together with our partners Medanco B.V. and AIM B.V., and with the support of Stimulus, we are advancing the development of the Laprixa System. This cutting-edge technology enables surgeons to assess bowel tissue perfusion in real-time, providing patient-specific insights during surgeries to help prevent serious complications such as anastomotic leakage.

​

Through this new OP-Zuid project, we are enhancing the system by integrating oxygen saturation measurements, offering an even more accurate prediction of wound healing capacity. We’re excited to collaborate with our partners to make this project a success and improve patient care!

#Innovation #MedTech #Collaboration #op_zuid #EFRO #Europe

After extensive review of Corporis Medical’s 510(k) pre-market submission, the FDA has granted its approval for the Mediclose System to enter the US market!

We are currently entertaining discussion with potential US distributors.

The Corporis Medical Team visited Medica and CompaMed last Tuesday, November 14, 2023. It was an interesting day filled with fruitful discussions and inspiring presentations. 

Klara Scupakova of Corporis Medical gave a Pitch about Corporis Medical and its products at the Brightlands Webinar on the opportunities in the health sector in the Netherlands and Catalonia.

Corporis Medical CSO Dr. Alexander Veenhof has successfully completed the first in vivo test for our latest innovation, “the miniaturized Laprixa probe”. Funded by Eurostars, the Obtain project incorporates the cutting-edge Laprixa tissue viability assessment technology into an 8mm probe, enhanced with a steerable head for improved surgical accessibility. In this pre-clinical in vivo test, blood pressure measurements were successfully taken, and the mechanical components performed flawlessly.

The next phase involves transitioning the prototype into a robust, manufacturable device, led by engineer Jason Millenaar in collaboration with injection molding specialists Samaplast. Additionally, software engineer Pim Nijdam, in partnership with Dynatron, is updating the Laprixa module and software to enable measurement of multiple soft tissues with greater accuracy.

This milestone signifies a major advancement in surgical technology, promising to offer surgeons a superior tool for predicting wound healing capacity of tissue during surgery. Corporis Medical continues to innovate, pushing the boundaries of medical technology.

Led by our CSO and founder Alexander Veenhof, Corporis Medical’s Mediclose System has been validated in patients in a multicenter First-in-Human clinical investigation. With this, we have demonstrated that the Mediclose System is safe for use and reduces port closure time significantly, compared to manual closure.

We are happy to announce that Corporis Medical is re-certified according to the ISO 13485:2016 standard. The re-certification audit by our notified body DEKRA, was passed with zero findings and no non-conformities.

Corporis Medical has obtained the EN ISO 13485:2016 certification after the successful audit in June 2020 for the design, development, manufacturing and distribution of devices for minimally invasive procedures.

This past Tuesday, the Corporis Medical team attended TEFAF Maastricht, courtesy of Brightlands. Our device The Mediclose System was also on display during the Brightlands Symposium that day. Thanks Brightlands for this opportunity!

Corporis Medical completed an all equity financing round, including the conversion of existing convertible loans. The round was led by Unorthodox Ventures, a venture capital firm based in Austin, Texas, with participation from existing investors, including Brightlands Ventures Partners and LIOF.

Proceeds will be used to fund a Randomized Controlled Trial for Mediclose, as well as clinical validation of the fully integrated Laprixa System. “We are pleased that Unorthodox Ventures and our current stakeholders have shown unwavering confidence in our products that improve outcomes of surgical interventions. This round of funding will allow us to take important steps necessary to enable a market launch” said John Marugg, Chief Executive Officer of Corporis Medical.

EIT Health awards Corporis Medical's “Objective surgical wound healing indicator” with the Quality Label. Following the Business Plan 2022 Call Evaluation by an international panel of independent experts, the proposal was scored as a high-quality project proposal in a highly competitive evaluation process. This project is recommended by EIT Health for additional funding sources.